{"groups":[{"description":"Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.\n\nDoxycycline: Doxycycline will be continued until one of the following criteria is met:\n\n* Patient has completed 1 year of doxycycline therapy\n* Patient develops any grade 3-4 toxicity related to doxycycline use.","id":"FG000","title":"Doxycycline (Localized Disease)"},{"description":"Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.\n\nDoxycycline: Doxycycline will be continued until one of the following criteria is met:\n\n* Patient has completed 1 year of doxycycline therapy\n* Patient develops any grade 3-4 toxicity related to doxycycline use.","id":"FG001","title":"Doxacycline (Systemic Disease)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Subjects were stratified by the type of amyloidosis. Subjects with primarily organ-based disease were classified as Localized Disease), whereas subjects with hematologic disease were classified as Systematic Disease. Each population received the same intervention but assessment of the clinical outcomes used different classification categories."}